(Q38177749)

30 August 2017

Behçet's syndrome pathophysiology and potential therapeutic targets (English)

1 reference

30 August 2017

0 references

1 reference

Mario Milco D'Elios

4

0 references

Domenico Prisco

object named as

Domenico Prisco

series ordinal

6

0 references

Giacomo Emmi

series ordinal

1

object named as

Giacomo Emmi

1 reference

30 August 2017

3

Danilo Squatrito

1 reference

30 August 2017

7

Lorenzo Emmi

1 reference

30 August 2017

2

Elena Silvestri

1 reference

30 August 2017

Lucia Ciucciarelli

5

1 reference

30 August 2017

12 January 2014

1 reference

Internal and emergency medicine

30 August 2017

1 reference

30 August 2017

9

1 reference

30 August 2017

3

1 reference

30 August 2017

257-265

1 reference

https://scigraph.springernature.com/pub.10.1007/s11739-013-1036-5

30 August 2017

0 references

cites work

HLA-B*51 and Behçet Disease

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Behçet's disease, the Silk Road and HLA-B51: historical and geographical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Identification of a susceptibility locus in STAT4 for Behçet's disease in Han Chinese in a genome-wide association study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Skin prick test with self-saliva in patients with oral aphthoses: a diagnostic pathergy for Behcet's disease and recurrent aphthosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Human 60-kDa heat shock protein is a target autoantigen of T cells derived from atherosclerotic plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Behçet's syndrome and micro-organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Fine antigen specificity of human gamma delta T cell lines (V gamma 9+) established by repetitive stimulation with a serotype (KTH-1) of a gram-positive bacterium, Streptococcus sanguis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Expansion of gammadelta T-cells in Behçet's disease: role of disease activity and microbial flora in oral ulcers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Immunopathogenesis of Behçet's disease with special emphasize on the possible role of antigen presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

New insights into the pathogenesis of Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Behçet's disease and genes within the major histocompatibility complex region

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Nitric oxide, lipid peroxidation and antioxidant defence system in patients with active or inactive Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Clinical targeting of the TNF and TNFR superfamilies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Vgamma9/Vdelta2 T lymphocytes in Italian patients with Behçet's disease: evidence for expansion, and tumour necrosis factor receptor II and interleukin-12 receptor beta1 expression in active disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Diversity of gammadelta T cells in patients with Behcet's disease is indicative of polyclonal activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Phenotype and functional changes of Vgamma9/Vdelta2 T lymphocytes in Behçet's disease and the effect of infliximab on Vgamma9/Vdelta2 T cell expansion, activation and cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Adalimumab for the treatment of Behçet's disease: experience in 19 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Association of specific interleukin 1 gene cluster polymorphisms with increased susceptibility for Behcet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Behçet's disease as an autoinflammatory disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Behçet's disease from the aspect of autoinflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Resistant Behçet disease responsive to anakinra

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Serum interleukin-6, procalcitonin and C-reactive protein levels in subjects with active Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Clinical characteristics of neuro-Behcet's disease in Japan: a multicenter retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Interferons, interferon-like cytokines, and their receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

BAFF is up-regulated in central nervous system of neuro-Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Release of B cell-activating factor of the TNF family in bronchoalveolar lavage from Behçet's disease with pulmonary involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

BAFF/BLyS inhibitors: A new prospect for treatment of systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Available evidence and outcome of off-label use of rituximab in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Behçet Disease-associated Uveitis Successfully Treated with Golimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Cytokines and Behcet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-013-1036-5

Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study

21 January 2018

1 reference

12 December 2020

Cytokine profile in Behçet uveitis.

1 reference

12 December 2020

Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.

1 reference

12 December 2020

Current and future treatments for Behçet's uveitis: road to remission

1 reference

12 December 2020

Serum BAFF levels and skin mRNA expression in patients with Behçet's disease.

1 reference

12 December 2020

One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet's disease refractory to standard immunosuppressive drugs

1 reference

12 December 2020

Neutrophil activation in Behçet's disease

1 reference

12 December 2020

The role of heat shock protein 60, vascular endothelial growth factor and antiphospholipid antibodies in Behçet disease

1 reference

12 December 2020

IFN-alpha blocks IL-17 production by peripheral blood mononuclear cells in Behcet's disease

1 reference

12 December 2020

Relationship between periodontal findings and specific polymorphisms of interleukin-1alpha and -1beta in Turkish patients with Behçet's disease

1 reference

12 December 2020

Kinetics of intraocular tumor necrosis factor and interleukin-6 in endotoxin-induced uveitis in the rat.

1 reference

12 December 2020

Association of salivary S. mutans colonisation and mannose-binding lectin deficiency with gender in Behçet's disease.

1 reference

12 December 2020

Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Behçet's disease. Does interleukin-1beta play a major role in Behçet's synovitis?

1 reference

12 December 2020

Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis

1 reference

12 December 2020

Genetics of Behçet disease inside and outside the MHC

1 reference

12 December 2020

Development of Immunopathogenesis Strategies to Treat Behçet's Disease

1 reference

12 December 2020

Refractory neuro-Behçet treated by tocilizumab: a case report

1 reference

12 December 2020

Streptococcal-related antigens stimulate production of IL6 and interferon-gamma by T cells from patients with Behcet's disease

1 reference

12 December 2020

Characterization of Streptococcus sanguis isolated from patients with Behçet's disease

1 reference

12 December 2020

Production of TNF-alpha and IL-1 in active Behçet's disease

1 reference

12 December 2020

Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects.

1 reference

12 December 2020

Skin hypersensitivity to streptococcal antigens and the induction of systemic symptoms by the antigens in Behçet's disease--a multicenter study. The Behcet's Disease Research Committee of Japan

1 reference

12 December 2020

Tocilizumab may be a potential addition to our weapons against neuro-Behçet’s disease

1 reference

12 December 2020

Induction of Behçet's disease symptoms after dental treatment and streptococcal antigen skin test

1 reference

12 December 2020

Tocilizumab treatment for neuro-Behcet's disease, the first report

1 reference

12 December 2020

Results of interferon-alfa therapy in patients with Behçet uveitis

1 reference

12 December 2020

Detection of microbial DNA in skin lesions from patients with Behçet's disease

1 reference

12 December 2020

HSP-derived peptides inducing uveitis and IgG and IgA antibodies

1 reference

12 December 2020

The role of streptococcal hypersensitivity in the pathogenesis of Behçet's Disease.

1 reference

12 December 2020

Anakinra for resistant Behçet uveitis: why not?

1 reference

12 December 2020

10.1007/S11739-013-1036-5

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24415351